Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-013383
Filing Date
2022-08-12
Accepted
2022-08-11 20:02:14
Documents
53
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q capr-20220630x10q.htm   iXBRL 10-Q 1259356
2 EX-31.1 capr-20220630xex31d1.htm EX-31.1 9524
3 EX-31.2 capr-20220630xex31d2.htm EX-31.2 9386
4 EX-32.1 capr-20220630xex32d1.htm EX-32.1 5744
5 EX-32.2 capr-20220630xex32d2.htm EX-32.2 5705
  Complete submission text file 0001558370-22-013383.txt   5118237

Data Files

Seq Description Document Type Size
6 EX-101.SCH capr-20220630.xsd EX-101.SCH 42666
7 EX-101.CAL capr-20220630_cal.xml EX-101.CAL 40088
8 EX-101.DEF capr-20220630_def.xml EX-101.DEF 153935
9 EX-101.LAB capr-20220630_lab.xml EX-101.LAB 318049
10 EX-101.PRE capr-20220630_pre.xml EX-101.PRE 263304
47 EXTRACTED XBRL INSTANCE DOCUMENT capr-20220630x10q_htm.xml XML 748426
Mailing Address 8840 WILSHIRE BLVD 2ND FLOOR BEVERLY HILLS CA 90211
Business Address 8840 WILSHIRE BLVD 2ND FLOOR BEVERLY HILLS CA 90211 (310) 358-3200
CAPRICOR THERAPEUTICS, INC. (Filer) CIK: 0001133869 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34058 | Film No.: 221157466
SIC: 2834 Pharmaceutical Preparations